Genetic variants in DNA repair predicts the survival of patients with esophageal cancer

Annals of Surgery

Volumn 253, Issue 5, 2011, Pages 918-927

  Lee, Jang Ming ^a   Yang, Pei Wen ^a   Yang, Shi Yi ^b   Chuang, Tzu Hsuen ^a   Tung, En Chi ^a   Chen, Jin Shing ^a   Huang, Pei Ming ^a   Lee, Yung Chie ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c 7 Chung Shan South Rd ^*  (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERCC4; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHINESE; DNA POLYMORPHISM; DNA REPAIR; ESOPHAGUS CANCER; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION;

ADULT; AGED; CHINA; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DNA REPAIR; DNA-BINDING PROTEINS; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 79954467237     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318216f374     Document Type: Article

References (52)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23): 2241-2252. (Pubitemid 37485141)
2. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53(1):5-26.
3. Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol. 1994;21(4):403-410. (Pubitemid 24256829)
4. Liang K, Ang KK, Milas L, et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 2003;57(1):246-254. (Pubitemid 36959763)
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
6. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery comparedwith surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337(3):161-167. (Pubitemid 27306287)
7. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339(27):1979-1984. (Pubitemid 29024130)
8. Yang HX, Xu Y, Fu JH, et al. An evaluation of the number of lymph nodes examined and survival for node-negative esophageal carcinoma: data from china. Ann Surg Oncol. 2010.
9. Hsu PK, Wu YC, Chou TY, et al. Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma. Ann Thorac Surg. 2010;89(4):1024-1031.
10. Morgan MA, Lewis WG, Casbard A, et al. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. Br J Surg. 2009;96(11):1300-1307.
11. Abate E, DeMeester SR, Zehetner J, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg. 2010;210(4):428-435.
12. DasA, Singh V, FleischerDE, et al.Acomparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol. 2008;103(6):1340-1345. (Pubitemid 351813937)
13. Abrams JA, Buono DL, Strauss J, et al. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer. 2009;115(21):4924-4933.
14. Ishihara R, Tanaka H, Iishi H, et al. Long-term outcome of esophageal mucosal squamous cell carcinoma without lymphovascular involvement after endoscopic resection. Cancer. 2008;112(10):2166-2172. (Pubitemid 351628625)
15. Kunisaki C, Makino H, Takagawa R, et al. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg. 2008;12(5):802-810.
16. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291-1295. (Pubitemid 351413906)
17. Laine JP, Mocquet V, Bonfanti M, et al. Common XPD (ERCC2) polymorphisms have no measurable effect on nucleotide excision repair and basal transcription. DNA Repair (Amst). 2007;6(9):1264-1270. (Pubitemid 47243714)
18. Wang XW, Vermeulen W, Coursen JD, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 1996;10(10):1219-1232. (Pubitemid 26171103)
19. Robles AI, Wang XW, Harris CC. Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53- mediated apoptotic cell death. Oncogene. 1999;18(33):4681-4688. (Pubitemid 29417743)
20. Yin J, Li J,Ma Y, et al. The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population. Cancer Lett. 2005;223(2):219-226. (Pubitemid 40719620)
21. Garcia-Closas M, Malats N, Real FX, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(3):536-542.
22. Worrillow L, Roman E, Adamson PJ, et al. Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma. Cancer Epidemiol. 2009;33(3-4):257-260.
23. WrenschM, Kelsey KT, LiuM, et al. ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol. 2005;7(4):495-507. (Pubitemid 41555621)
24. Liu P, Siciliano J, White B, et al. Regional mapping of human DNA excision repair gene ERCC4 to chromosome 16p13.13-p13. Mutagenesis. 1993;8(3):199-205. (Pubitemid 23177687)
25. Gillet LC, Scharer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev. 2006;106(2):253-276.
26. Klopp AH, Jhingran A, Ramdas L, et al. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. Int J Radiat Oncol Biol Phys. 2008;71(1):226-236. (Pubitemid 351491407)
27. Murray D, Rosenberg E. The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res. 1996;364(3):217-226. (Pubitemid 26408461)
28. Shao M, Ma H, Wang Y, et al. Polymorphisms in excision repair crosscomplementing group 4 (ERCC4) and susceptibility to primary lung cancer in a Chinese Han population. Lung Cancer. 2008;60(3):332-339.
29. Greene FL, Page DL, Fleming ID. Esophagus in: American Joint Committee on Cancer (AJCC) Cancer Staging Manual 6th ed. New York, NY. Springer; 2002:167-178.
30. Korst RJ, Kansler AL, Port JL, et al. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg. 2006;82(2):480-484; discussion 484-485.
31. Japanese Committee for Registration of Esophageal Carcinoma. A proposal for a new TNM classification of esophageal carcinoma. Jpn J Clin Oncol. 1985;15(4):625-636.
32. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classifi- cation. Ann Surg. 2005;242(5):684-692. (Pubitemid 41567124)
33. Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007;31(1):58-64. (Pubitemid 46036902)
34. Lee JM, Lo AC, Yang SY, et al. Association of angiotensin-converting enzyme insertion/deletion polymorphism with serum level and development of pulmonary complications following esophagectomy. Ann Surg. 2005;241(4): 659-665.
35. Bosken CH,Wei Q, Amos CI, et al. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst. 2002;94(14):1091-1099. (Pubitemid 34830729)
36. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127(3):978-983. (Pubitemid 40775532)
37. Wolfe KJ, Wickliffe JK, Hill CE, et al. Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics. 2007;17(11):897-905. (Pubitemid 350293790)
38. RoyD,Guida P, Zhou G, et al.Gene expression profiling of breast cells induced by X-rays and heavy ions. Int J Mol Med. 2008;21(5):627-636.
39. Milne RL, Ribas G, Gonzalez-Neira A, et al. ERCC4 associated with breast cancer risk: a two-stage case-control study using high-throughput genotyping. Cancer Res. 2006;66(19):9420-9427. (Pubitemid 44623638)
40. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22(13):2594- 2601. (Pubitemid 41103746)
41. Gu J, Zhao H, Dinney CP, et al.Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res. 2005;11(4):1408-1415. (Pubitemid 40315220)
42. Sakano S, Wada T, Matsumoto H, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer. 2006;95(5): 561-570. (Pubitemid 44325895)
43. Li H, Zhang Q,Xu L, et al. Factors predictive of prognosis after esophagectomy for squamous cell cancer. J Thorac Cardiovasc Surg. 2009;137(1):55-59.
44. Caronia D, Patino-Garcia A, Milne RL, et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 2009;9(5): 347-553.
45. Gangawar R, Ahirwar D, Mandhani A, et al. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India. Med Oncol. 2010;27(2): 159-66.
46. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, andXPD polymorphismswith response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797-1803.
47. Monzo M, Moreno I, Navarro A, et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology. 2007;72(5-6):364-370. (Pubitemid 351238151)
48. Le Morvan V, Smith D, Laurand A, et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics. 2007;8(12):1693-1703.
49. Vangsted A, Gimsing P, Klausen TW, et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer. 2007;120(5):1036-1045. (Pubitemid 46214303)
50. Quintela-Fandino M, Hitt R, Medina PP, et al.DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol. 2006;24(26):4333-4339. (Pubitemid 46630792)
51. Allan JM, Smith AG, Wheatley K, et al. Genetic variation in XPD predicts treatment outcome and risk of acutemyeloid leukemia following chemotherapy. Blood. 2004;104(13):3872-3877. (Pubitemid 39620132)
52. Bradbury PA, Kulke MH, Heist RS, et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics. 2009;19(8):613-625.